SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-004201
Filing Date
2024-01-30
Accepted
2024-01-29 19:28:20
Documents
17
Period of Report
2024-01-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38022
2 ex99-1.htm EX-99.1 14287
3 ex99-1_001.jpg GRAPHIC 9957
  Complete submission text file 0001493152-24-004201.txt   281945

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lixt-20240129.xsd EX-101.SCH 3519
5 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lixt-20240129_def.xml EX-101.DEF 26564
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lixt-20240129_lab.xml EX-101.LAB 36548
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lixt-20240129_pre.xml EX-101.PRE 25188
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5214
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 24575399
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)